Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. engages in the research and development, production, and sale of vitro diagnostic reagents and diagnostic instruments in China. The company offers external diagnostic testing, third-party medical testing, certification consulting services, and medical information platform construction services. It also provides information software and supporting hardware… Read more
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A - Asset Resilience Ratio
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) has an Asset Resilience Ratio of 6.64% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥404.92 Million | 6.64% |
| Total Liquid Assets | CN¥404.92 Million | 6.64% |
Asset Resilience Insights
- Limited Liquidity: Wuhan Easy Diagnosis Biomedicine Co Ltd Class A maintains only 6.64% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A Industry Peers by Asset Resilience Ratio
Compare Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022 |
Medical Devices | 0.01% |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.26% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 7.79% |
|
Shinhung
KO:004080 |
Medical Devices | 4.17% |
|
UMediC Group Berhad
KLSE:0256 |
Medical Devices | 1.48% |
|
Osang Healthcare Co.,Ltd
KQ:036220 |
Medical Devices | 9.34% |
|
HansBiomed Corporation
KQ:042520 |
Medical Devices | 9.13% |
|
JVM Co. Ltd
KQ:054950 |
Medical Devices | 41.09% |
Annual Asset Resilience Ratio for Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Wuhan Easy Diagnosis Biomedicine Co Ltd Class A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.97% | CN¥64.12 Million | CN¥6.59 Billion | -0.69pp |
| 2023-12-31 | 1.66% | CN¥122.59 Million | CN¥7.39 Billion | -19.59pp |
| 2022-12-31 | 21.25% | CN¥1.95 Billion | CN¥9.19 Billion | +0.76pp |
| 2021-12-31 | 20.49% | CN¥700.00 Million | CN¥3.42 Billion | +6.47pp |
| 2020-12-31 | 14.02% | CN¥200.00 Million | CN¥1.43 Billion | -17.31pp |
| 2019-12-31 | 31.33% | CN¥200.00 Million | CN¥638.42 Million | -- |